Pfizer continues to make headlines with its COVID-19 initiatives, but the company prides itself in all of its scientific achievements and the financial muscle to back them up.
2021 marks the third edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation.
The pharmaceutical industry drew together in 2020 to fight the COVID-19 pandemic, and while the battle continues, pharma companies have even more going on.
Five years after bottoming out, Bristol Myers Squibb has moved to the first division of pharma companies with three of the world’s top eight drugs in its portfolio.
GSK continues to increase investment in the company pipeline, build on top-line momentum for key growth drivers, and largely complete readiness for the consumer healthcare business separation.
As global corporations reach deeper into every part of our lives, marketing is evolving into something unrecognizable. According to Michael Farmer, in the Mad Men Era of the 1960s and 70s, your average creative agency was responsible for roughly 350 deliverables a year—whether they were print copy, radio scripts, or billboard headlines. Today? The average number of deliverables per creative per year is over 10,000.
Humira could generate more than $20 billion in sales for AbbVie during 2021 while Merck’s Keytruda is on track to become only the second prescription medicine ever to exceed $16 billion in annual sales.
With more than half of the U.S. population fully vaccinated and mask mandates being lifted throughout the country, America looks to resume “normal life” before the pandemic took over.
After one full year when just about everyone who could was working from home, healthcare advertising agencies have managed to adapt and thrive, using technology to serve their clients, onboard new employees, and create bonds.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.